MAP3K14 and cancer: The exclusion of participants with hs-CRP ≥ 10 mg/l (n = 67) or the exclusion of participants with cancer in active treatment, diagnosis of diabetes and treatment of CVD within a year in both time points (n = 1000) did not affect the results of main analyses.